Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effect of PH-797804 following dosing of a 24 mg oral tablet on the QTc interval
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PH-797804 | Experimental | Subjects will receive a single 24 mg dose in the fed state |
|
| Moxifloxacin | Experimental | Subjects will receive a single 400 mg dose in the fed state |
|
| Placebo | Experimental | Subjects will receive a single placebo dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PH-797804 | Drug | Tablet, 24 mg, single dose |
| |
| Moxifloxacin |
| Measure | Description | Time Frame |
|---|---|---|
| QTcF Interval | QT interval corrected for heart rate using Fredericias correction | -1.5,-1,-0.5,0.5,2,4,5,6,7,8,12,24 hours post-dose |
| Measure | Description | Time Frame |
|---|---|---|
| QTcI Interval | QT interval using individual heart rate correction | -1.5,-1,-0.5,0.5,2,4,5,6,7,8,12,24 hours post-dose |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | New Haven | Connecticut | 06511 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C542398 | PH 797804 |
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Tablet, 400 mg, single dose |
|
| Placebo | Drug | Tablet, PH-797804 matched placebo, single dose |
|
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
| 0,0.5,2,4,5,6,7,8,12,24 hours post-dose |
| Maximum Observed Plasma Concentration (Cmax) | 0,0.5,2,4,5,6,7,8,12,24 hours post-dose |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0,0.5,2,4,5,6,7,8,12,24 hours post-dose |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |